Jeffrey A Klomp

8PUBLICATIONS
93CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 08, 2026
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer.

|Sep 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.

Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp

|Jul 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.

Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp

|Feb 20, 2025
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress.

Jay R Anand, Gaith N Droby, Sayali Joseph

|Oct 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.

Xiuting Liu, John M Baer, Meredith L Stone

|Jun 06, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.

Jeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker

Pageof 2

Frequent Collaborators

7 joint publications

Channing J Der

6 joint publications

Clint A Stalnecker

6 joint publications

Kirsten L Bryant

6 joint publications

Adrienne D Cox